secwatch.observer — SEC 8-K summary
======================================

Issuer:     FATE THERAPEUTICS INC (FATE)
CIK:        0001434316
Form:       8-K
Filed at:   2024-11-29T23:59:59+00:00
Accession:  0001193125-24-268003
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fate Therapeutics CEO Scott Wolchko to retire Dec 31; succeeded by Bob Valamehr
-------------------------------------------------------------------------------

- Wolchko resigned from board Nov 27, 2024; will retire as President & CEO effective Dec 31, 2024.
- Valamehr, currently President of R&D, becomes President & CEO Jan 1, 2025; also named director.
- Wolchko to remain a strategic advisor after retirement; resignation not due to any disagreement.
- Valamehr has led iPSC platform development ~15 years; oversaw 13 IND applications and pipeline.
- FT819 SLE trial: first patient achieved drug-free remission after single dose; no dose-limiting toxicities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434316/000119312524268003/0001193125-24-268003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434316/000119312524268003/d816234d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-268003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer